header advert
Orthopaedic Proceedings Logo

Receive monthly Table of Contents alerts from Orthopaedic Proceedings

Comprehensive article alerts can be set up and managed through your account settings

View my account settings

Visit Orthopaedic Proceedings at:

Loading...

Loading...

Full Access

COMPLICATIONS FOLLOWING SHOULDER SURGERY – ANALYSIS USING NATIONAL HOSPITAL EPISODE STATISTICS



Abstract

Background: Diagnostic and operative codes are routinely collected on every patient admitted to hospital in England and Wales (hospital episode statistics, HES). Linked data allows post-operative complications to be associated with the primary operative procedure, even if patients are re-admitted following a successful discharge. Morbidity and mortality data on shoulder surgery have not previously been available in large numbers.

Methods: All HES data for a 42-month was analysed and divided into three groups – elective shoulder replacement (total or hemiarthroplasty), shoulder arthroscopy (all procedures), and proximal humerus fracture surgery (internal fixation or replacement). Incidence of pulmonary embolism (PE), deep venous thrombosis (DVT) and mortality within 90 days was established.

Results: For elective shoulder replacement (10735 patients), 90-day DVT, PE and mortality rates were 0.07%, 0.11% and 0.36% respectively. Mortality in patients over 75 years was 0.9%. For arthroscopic procedures (66344 patients), 90-day DVT, PE and mortality rates were 0.01%, 0.01% and 0.03%. For proximal humerus fracture surgery (internal fixation or replacement, 4968 patients) 90-day DVT, PE and mortality rates were 0.20%, 0.38% and 2.98%. Mortality in patients over 75 years old was 6.6%.

Discussion: Venous thromboembolic (VTE) prophylaxis is rarely used for upper limb surgery. PE and mortality rates for shoulder replacement and proximal humerus fracture surgery are lower those for patients receiving chemical prophylaxis after hip replacement. Further investigation into the cause of high mortality rates following fracture surgery in patients over 75 years old is required. VTE prophylaxis may be required in this age group.


Correspondence should be sent to Mr Simon Jameson, Wansbeck Hospital, Newcastle, United Kingdom, simonjameson@doctors.org.uk

The abstracts were prepared by Mr Matt Costa and Mr Ben Ollivere. Correspondence should be addressed to Mr Costa at Clinical Sciences Research Institute, University of Warwick, Clifford Bridge Road, Coventry CV2 2DX, UK.